ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 538,29
-0,30%
Dow Jones
39 331,85
0,41%
DAX
18 164,06
-0,86%
Brent Oil
86,275
-0,20%
Bitcoin
62 177,06
0,24%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ocular Therapeutix Inc (OCUL)

  7. Ocular Therapeutix Inc (OCUL) Actualités

OCUL

Ocular Therapeutix (OCUL)

Ocular Therapeutix Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OCUL
DateHeureSourceTitreSymboleSociété
17/06/202422h12Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
14/06/202415h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
13/06/202422h05GlobeNewswire Inc.Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR StudyNASDAQ:OCULOcular Therapeutix Inc
05/06/202413h30GlobeNewswire Inc.Ocular Therapeutix® to Host Investor Day on June 13, 2024NASDAQ:OCULOcular Therapeutix Inc
04/06/202423h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
04/06/202423h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
04/06/202422h05GlobeNewswire Inc.Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
30/05/202423h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
07/05/202422h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCULOcular Therapeutix Inc
07/05/202422h05GlobeNewswire Inc.Ocular Therapeutix™ Reports First Quarter 2024 ResultsNASDAQ:OCULOcular Therapeutix Inc
07/05/202422h01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:OCULOcular Therapeutix Inc
07/05/202402h16GlobeNewswire Inc.Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
06/05/202413h30GlobeNewswire Inc.Ocular Therapeutix™ to Present at Two Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
03/05/202413h30GlobeNewswire Inc.Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024NASDAQ:OCULOcular Therapeutix Inc
01/05/202413h30GlobeNewswire Inc.Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024NASDAQ:OCULOcular Therapeutix Inc
11/03/202421h12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OCULOcular Therapeutix Inc
11/03/202411h39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:OCULOcular Therapeutix Inc
19/02/202415h00PR Newswire (US)AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic ConjunctivitiNASDAQ:OCULOcular Therapeutix Inc
15/02/202414h00GlobeNewswire Inc.Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial OfficerNASDAQ:OCULOcular Therapeutix Inc
15/02/202401h48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCULOcular Therapeutix Inc
13/02/202413h37GlobeNewswire Inc.Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
28/12/202322h17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:OCULOcular Therapeutix Inc
18/12/202322h52Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OCULOcular Therapeutix Inc
18/12/202322h01GlobeNewswire Inc.Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:OCULOcular Therapeutix Inc
14/12/202322h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCULOcular Therapeutix Inc
14/12/202304h09GlobeNewswire Inc.Ocular Therapeutix™ Announces Pricing of Public Offering of Common StockNASDAQ:OCULOcular Therapeutix Inc
14/12/202301h07Dow Jones NewsStocks to Watch: Adobe, Amtech Systems, Ocular TherapeutixNASDAQ:OCULOcular Therapeutix Inc
13/12/202322h01GlobeNewswire Inc.Ocular Therapeutix™ Announces Proposed Public Offering of Common StockNASDAQ:OCULOcular Therapeutix Inc
17/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCULOcular Therapeutix Inc
08/11/202314h00GlobeNewswire Inc.Ocular Therapeutix™ to Present at Three Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
 Showing the most relevant articles for your search:NASDAQ:OCUL

Dernières Valeurs Consultées

NYSE
KO
Coca Cola
NASDAQ
GOOGL
Alphabet
EU
CS
Axa
USI
USTECH100
US Tech 100
NASDAQ
MSFT
Microsoft
EU
DG
Vinci
EU
LR
Legrand
EU
MC
Lvmh Moet Hennessy Louis...
SPI
SP500
S&P 500
EU
CAP
Capgemini
EU
AF
Air FranceKLM
NYSE
NKE
Nike
EU
VIV
Vivendi
COIN
BTCUSD
Bitcoin
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés